Trials / Completed
CompletedNCT01642667
Pharmacoinvasive Therapy With Prourokinase
The Efficacy and Safety of Pharmacoinvasive Therapy With Prourokinase for Acute ST Segment Elevation Myocardial Infarction Patients With Expected Percutaneous Coronary Intervention Related Delay
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 197 (actual)
- Sponsor
- Suzhou Landing Pharmaceuticals · Academic / Other
- Sex
- All
- Age
- 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prourokinase | a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min. |
| DRUG | Placebo |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-11-01
- Completion
- 2010-12-01
- First posted
- 2012-07-17
- Last updated
- 2012-07-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01642667. Inclusion in this directory is not an endorsement.